Free Trial
NASDAQ:MBOT

Microbot Medical Q2 2024 Earnings Report

Microbot Medical logo
$1.77 -0.05 (-2.75%)
Closing price 04:00 PM Eastern
Extended Trading
$1.78 +0.01 (+0.79%)
As of 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Microbot Medical EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.17
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Microbot Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Microbot Medical Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Microbot Medical's next earnings date is estimated for Tuesday, August 11, 2026, based on past reporting schedules.

Conference Call Resources

Microbot Medical Earnings Headlines

Musk is burning $2.5 billion a quarter on AI. One company holds the key.
SpaceX's S-1 filing reveals $7.7 billion spent on AI infrastructure in a single quarter - not chips, not software, but power infrastructure. The filing shows $23.85 billion in servers and $14 billion in construction in progress, all dependent on one company's hardware. Without this supplier, Colossus doesn't run and the $1.25 billion Anthropic pays monthly stops flowing. The stock is still trading like no one has read the filing - but analyst Dylan Jovine has, and he's releasing the name at no cost.tc pixel
See More Microbot Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Microbot Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Microbot Medical and other key companies, straight to your email.

About Microbot Medical

Microbot Medical (NASDAQ:MBOT) (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease. The endoluminal platform targets gastrointestinal and urogenital tracts, employing swallowable or catheter-deployed microbots to biopsy tissue, administer local therapy or assist in endoscopic procedures.

Headquartered in Ra’anana, Israel, with U.S. operations in Boston, Massachusetts, Microbot Medical collaborates with leading academic and clinical research centers to advance its pipeline through preclinical studies and early-stage human trials. Under the leadership of CEO Ohad Arazi, the company seeks regulatory approvals and strategic partnerships to bring its microbot platforms to global markets in Europe, North America and Asia.

View Microbot Medical Profile